Meta-analysisindependent cross-checkfull text checked★ key study I-ABX-102 in-depth review
Antibiotics help children with pneumonia
Oral amoxicillin for management of fast breathing or chest indrawing pneumonia without danger signs in children aged 2-59 months: a systematic review and meta-analysis.
Overview
Gadapani Pathak B et al.. J Glob Health 2026 · PMID 42725565 · DOI 10.7189/jogh.16.04209
In randomised trials of young children with mild pneumonia, amoxicillin reduced treatment failure compared with no antibiotic.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test whether amoxicillin helps young children with mild pneumonia
- How was the study done?
Meta-analysis of 4 randomised trials
- How many people, animals or samples were studied?
7699 children aged 2-59 months
- What was actually found?
Fewer treatment failures with amoxicillin
- How large was the observed effect?
RR 0.84 (0.75-0.94); NNT about 43 in the largest trial
- What do the results mean in everyday life?
Children with pneumonia should be assessed and treated by health workers; antibiotics reduce failures
- What are the study's limitations?
Mostly mild cases in low-resource countries; one trial at high risk of bias
- What does it say about Elawady's specific claim?
Contradicts the advice that no child should receive antibiotics
- Do the results apply to Germany and Europe?
Moderate
- What can explicitly not be concluded from this study?
Effects in severe pneumonia (no placebo trials exist because withholding treatment would be unsafe)
Scientific in-depth review
1. Full reference
- Authors
- Gadapani Pathak B et al.
- Journal
- J Glob Health
- Year
- 2026
- Identifier
- PMID 42725565 DOI 10.7189/jogh.16.04209
- Verification
- verified – PubMed efetch 2026-10-26 + Crossref
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Funded by WHO (grant 2023/1368179-0) to the Society for Applied Studies; one co-author is a WHO employee (full text).
2. Research question
In children aged 2-59 months with fast-breathing pneumonia, does oral amoxicillin reduce treatment failure compared with no antibiotics?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis of randomised trials (WHO guideline evidence review)
- Population
Children aged 2-59 months with WHO-defined fast-breathing pneumonia (and chest-indrawing pneumonia without danger signs) in low- and middle-income countries
- Country
India, Pakistan, Malawi (fast-breathing trials)
- Period
Trials published January 2000-August 2024
- Sample size
4 RCTs, 7699 children (amoxicillin vs no antibiotics/placebo); 3 RCTs, 4864 children (oral vs injectable)
- Inclusion and exclusion criteria
Randomised and quasi-randomised trials; children 2-59 months
4. Methods and endpoints
- Exposure / intervention
Oral amoxicillin (3 days)
- Comparator
No antibiotics or placebo
- Endpoints
Treatment failure at day 14; relapse; adverse events; mortality
- Statistical methods
Random-effects pooled RR; RoB 2; GRADE
5. Actual results
- Results
Fast-breathing pneumonia: amoxicillin reduced treatment failure at day 14, RR 0.84 (95% CI 0.75-0.94; I2 0%; moderate certainty). Largest trial (Jehan 2020, Pakistan, 4002 children): risk difference 2.3 percentage points (0.9-3.7) in favour of amoxicillin (Table 1). Chest-indrawing pneumonia: oral vs injectable similar treatment failure; mortality RR 0.28 (0.09-0.86) favouring oral amoxicillin.
- Absolute risks
Jehan 2020: risk difference 2.3 percentage points; NNT about 43 (recalculated)
- Authors' conclusion
Oral amoxicillin significantly reduces treatment failure compared with no antibiotics for fast-breathing pneumonia in children.
6. Strengths
- RCTs only
- Low heterogeneity
- GRADE and RoB 2
- Recent (post-vaccine) trials included
- Full text read
7. Weaknesses
- One of four trials at high risk of bias
- Low-resource settings; mostly mild pneumonia
- Funded by WHO to inform its own guideline
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Pre-registered (PROSPERO CRD42023439851); certainty moderate for the main outcome.
9. Assessment of the statistical interpretation
A 16% relative reduction with a small absolute difference (most untreated children with mild fast-breathing pneumonia recovered), but antibiotics still prevented failures. Pooled RR CI is log-symmetric.
10. Relevance to the specific claim
Direct randomised evidence in children: withholding antibiotics in pneumonia increases treatment failure, even in the mildest WHO category.
11. Independent contrary findings
Most children recovered without antibiotics; benefit is modest in absolute terms in mild fast-breathing pneumonia. Severe pneumonia was not tested against no treatment (it would be unethical).
12. Transferability to Germany and Europe
Moderate: LMIC trials; principle transferable, absolute risks differ.
13. Overall methodological judgement
High-quality evidence that even mild childhood pneumonia does better with antibiotics; contradicts 'nobody should take antibiotics'.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Which subgroups (e.g. viral bronchiolitis) can safely go without antibiotics.
15. Linked fact checks
- Antibiotics should not be used as a treatment at all; nobody should take an antibiotic for any reason (not even after a tooth extraction); the body can cope on its own. – Studies contradicting or limiting the claim